Carbonic anhydrase (CA)
Carbonic anhydrase refers to a family of zinc-containing metalloenzymes that catalyze the reversible interconversion of carbon dioxide and water to bicarbonate and protons.
Carbonic anhydrase refers to a family of zinc-containing metalloenzymes that catalyze the reversible interconversion of carbon dioxide and water to bicarbonate and protons. This reaction is central to physiological acid–base balance, CO2 transport, ion transport, and fluid secretion. Carbonic anhydrases are widely expressed across tissues and include multiple isoforms with distinct cellular localizations and biological roles.
From a biomedical perspective, carbonic anhydrases are important because altered isoform expression can contribute to disease processes, including tumor progression and dysregulated pH homeostasis. In drug discovery, they are established targets for both inhibition and activation strategies. Tumor-associated isoforms such as CA IX and CA XII are especially relevant in oncology, while brain-associated isoforms such as CA VII are being explored as targets for selective activation. Because these enzymes sit at the interface of metabolism, pH regulation, and cellular adaptation, they are also of interest in biomaterials and biosensing applications.
Where the papers sit
11 papers from the last 6 months study Carbonic anhydrase (CA) directly · updated from PubMed 12 Nov 2026
Study type 0 clinical trials · 1 human data · 10 preclinical
Themes 3 themes · 1 new direction
-
Isoform-Selective Carbonic Anhydrase Inhibitors
Isoform-selective carbonic anhydrase inhibitors are being developed for cancer and antimycobacterial therapy rather than as nonspecific enzyme blockers. Benzenesulfonamides, pyrazoles and bendamustine hybrids target CA I, CA II, CA IX or CA XII, with some designs adding PRAK inhibition. Antiproliferative effects and cell-cycle arrest support oncology applications, while NSAID hybrids extend the strategy to mycobacterial disease. Subnanomolar potency is improving, but translating biochemical selectivity into disease-specific efficacy remains unresolved.
5 papers · 45.5%
-
Structure-Guided Carbonic Anhydrase Design
Sulfonamide-based scaffolds and multifunctional hybrids are being optimized as carbonic anhydrase inhibitors with anticancer or cognitive-disease applications. Acridinediones, pyrazolones and tacrine-celecoxib compounds recur, with molecular dynamics and binding analysis used to connect structure with inhibition. The work also probes how glutamate binding disrupts carbonic anhydrase structure and promotes aggregation. Selectivity, cellular activity and preservation of protein function remain open priorities.
4 papers · 36.4%
-
Brain Carbonic Anhydrase Inhibition
Brain carbonic anhydrase inhibition is being explored for Alzheimer’s disease, cerebrovascular stress and abnormal neuronal activity. Blocking mitochondrial CA-VB can reduce brain endothelial stress and improve memory in Alzheimer’s models. Separate slice experiments examine how inhibition changes H+ and Cl− transients and epileptiform activity, linking enzyme control to neuronal excitability. The field is moving toward CNS applications, but whether these effects generalize across cognition and epilepsy remains open.
2 papers · 18.2%
Glutamate can act directly on carbonic anhydrase to destabilize and aggregate the enzyme
The glutamate–carbonic anhydrase system in a neurodegeneration-relevant model 42276475Jun departs from the set’s usual treatment of CA as an enzyme to inhibit, target pharmacologically, or monitor: instead, pathological glutamate concentrations bind CA, suppress its activity, disrupt its secondary and tertiary structure, reduce its thermodynamic stability, and promote aggregation. This assigns CA a previously unrepresented role as a metabolite-vulnerable protein whose structural failure may itself link dysregulated neurotransmitter levels to neurodegenerative pathology.
Papers
The 11 papers from the last 6 months that study Carbonic anhydrase (CA) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Isoform-Selective Carbonic Anhydrase Inhibitors (5)
- Investigating the Inhibitory Properties of Diazo and Pyrazole-Carboxamide-Linked Benzenesulfonamides Against Carbonic Anhydrase Isoforms I, II, IX, and XII. ChemMedChem · 7 Jul 2026 PMID 42410713
- Rational design and synthesis of pyrazole-based sulfonamides as dual carbonic anhydrase and PRAK-targeting anticancer agents. Bioorganic chemistry · 29 Jun 2026 PMID 42372456
- Design and Synthesis of Bendamustine-Carbonic Anhydrase Inhibitors with Antiproliferative Effects in Clear Cell Renal Cell Carcinoma. Journal of medicinal chemistry · 24 Jun 2026 PMID 42339601
- Discovery of Subnanomolar and Highly Selective Carbonic Anhydrase II Inhibitors Featuring L-Shaped Scaffolds via Active-Site-Matched Fragment Growing. Journal of medicinal chemistry · 15 Jun 2026 PMID 42290333
- First-in-class nonsteroidal anti-inflammatory drug and carbonic anhydrase inhibitor hybrid compounds as effective antimycobacterial agents. European journal of medicinal chemistry · 12 Jun 2026 PMID 42284634
Structure-Guided Carbonic Anhydrase Design (4)
- Sulfonamide/Carboxylate Functionalized Acridinedione Derivatives: Design, Synthesis, and Carbonic Anhydrase Inhibition Profile. ChemMedChem · 10 Nov 2026 PMID 43004539
- Molecular signature exploration of novel Pyrazolone-derived sulfonamides against colorectal Cancer: Synthesis, biological profiling and computational modeling. Bioorganic chemistry · 27 Jun 2026 PMID 42364381
- Glutamate binding perturbs structure-function integrity of carbonic anhydrase and promotes its aggregation: Implications of dysregulated metabolite levels in neurodegeneration. International journal of biological macromolecules · 11 Jun 2026 PMID 42276475
- One destination, three routes: Tacrine-Celecoxib hybrids targeting cholinesterases, COX-2, and carbonic anhydrases in cognitive impairment linked to metabolic dysfunction. European journal of medicinal chemistry · 26 May 2026 PMID 42190432
Brain Carbonic Anhydrase Inhibition (2)
- Mitochondrial carbonic anhydrase-VB inhibition rescues brain endothelial stress and memory in Alzheimer's disease models. Science advances · 14 Oct 2026 PMID 42873864
- Effect of carbonic anhydrase inhibitor on H+- and Cl--transients and epileptiform activity in brain slices of ClopHensor-expressing transgenic mice. Neuroscience · 13 Jul 2026 PMID 42442454
By study type
Human data, design not indexed (1)
- Sulfonamide/Carboxylate Functionalized Acridinedione Derivatives: Design, Synthesis, and Carbonic Anhydrase Inhibition Profile. ChemMedChem · 10 Nov 2026 PMID 43004539
Preclinical: animal, cell and lab studies (10)
- Mitochondrial carbonic anhydrase-VB inhibition rescues brain endothelial stress and memory in Alzheimer's disease models. Science advances · 14 Oct 2026 PMID 42873864
- Effect of carbonic anhydrase inhibitor on H+- and Cl--transients and epileptiform activity in brain slices of ClopHensor-expressing transgenic mice. Neuroscience · 13 Jul 2026 PMID 42442454
- Investigating the Inhibitory Properties of Diazo and Pyrazole-Carboxamide-Linked Benzenesulfonamides Against Carbonic Anhydrase Isoforms I, II, IX, and XII. ChemMedChem · 7 Jul 2026 PMID 42410713
- Rational design and synthesis of pyrazole-based sulfonamides as dual carbonic anhydrase and PRAK-targeting anticancer agents. Bioorganic chemistry · 29 Jun 2026 PMID 42372456
- Molecular signature exploration of novel Pyrazolone-derived sulfonamides against colorectal Cancer: Synthesis, biological profiling and computational modeling. Bioorganic chemistry · 27 Jun 2026 PMID 42364381
- Design and Synthesis of Bendamustine-Carbonic Anhydrase Inhibitors with Antiproliferative Effects in Clear Cell Renal Cell Carcinoma. Journal of medicinal chemistry · 24 Jun 2026 PMID 42339601
- Discovery of Subnanomolar and Highly Selective Carbonic Anhydrase II Inhibitors Featuring L-Shaped Scaffolds via Active-Site-Matched Fragment Growing. Journal of medicinal chemistry · 15 Jun 2026 PMID 42290333
- First-in-class nonsteroidal anti-inflammatory drug and carbonic anhydrase inhibitor hybrid compounds as effective antimycobacterial agents. European journal of medicinal chemistry · 12 Jun 2026 PMID 42284634
- Glutamate binding perturbs structure-function integrity of carbonic anhydrase and promotes its aggregation: Implications of dysregulated metabolite levels in neurodegeneration. International journal of biological macromolecules · 11 Jun 2026 PMID 42276475
- One destination, three routes: Tacrine-Celecoxib hybrids targeting cholinesterases, COX-2, and carbonic anhydrases in cognitive impairment linked to metabolic dysfunction. European journal of medicinal chemistry · 26 May 2026 PMID 42190432
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-06-24. Last written: 2026-07-29 by GPT. Drafted by language models from published abstracts; not medical advice.